CurrentBlue Cross Blue Shield - NevadaPolicy 04-203

Biological Materials to Aid in Soft and Osseous Tissue Regeneration

This policy governs the clinical indications, documentation, and coding considerations for use of biological materials to aid soft and bone tissue regeneration in dental care when applicable under specific group contracts. It affects dentists and providers submitting claims to Blue Cross Blue Shield - Nevada where group contract coverage is required.

Policy Summary

PayerBlue Cross Blue Shield - Nevada

PolicyBiological Materials to Aid in Soft and Osseous Tissue Regeneration

Policy CodePolicy 04-203

Change TypeNo material changes

Effective DateJan 1, 2023

Next Review DateN/A

Key ActionProvide pretreatment periapical radiographs (dated within 12 months), current 6‑point periodontal charting, and a letter of rationale when submitting for coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3CDT codes listed

12 moRadiograph timeliness

6‑pointPeriodontal charting

4Required doc elements

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Indications and documentation criteria

Covered when ALL of the following are documented and coverage is allowed by the member's specific group contract:

Documentation requirements: 1) Pretreatment periapical radiographic images that are of diagnostic quality, properly oriented, identified, and dated current (within 12 months); 2) Current, dated periodontal charting (6‑point) indicating a minimum of 5 mm pocket depths; 3) A letter of rationale explaining the necessity of the regeneration procedure and the type of biologic material being used (examples that may be requested include platelet rich plasma [PRP], Emdogain, recombinant human bone morphogenic protein [rhBMP], GEM 21S9); 4) Note that use of biological materials may not be considered when used in conjunction with soft tissue grafting, bone grafts, guided tissue regeneration, ridge augmentation, periradicular surgery, placed within extraction sites, or when utilized with other regenerative materials regardless of specific group plan coverage.

Coverage only when allowed by the member's specific group contract

The policy specifies that use of biological materials may not be considered when they are applied in conjunction with certain other procedures. Specifically, coverage consideration may be limited or excluded when biologic materials are used with soft tissue grafting, bone grafts, guided tissue regeneration, ridge augmentation, periradicular surgery, placed within extraction sites, or when utilized with other regenerative materials. Whether these situations affect payment depends on the member's specific group contract and documentation provided.

The CDT codes listed in this policy are provided for informational purposes only and do not, by their inclusion or exclusion, guarantee that a service will be covered or reimbursed. Determination of coverage and any requirement for prior authorization are governed by the member's contract benefits in effect at the time of service and by medical necessity as documented by the provider. Examples of codes included for reference are D3431, D4265, and D4266.

Coding

CDT codes (informational)CPT

D3431	Biological materials to aid in soft and osseous tissue regeneration in conjunction with periradicular surgery
D4265	Biologic materials to aid in soft and osseous tissue regeneration, per site
D4266	Guided tissue regeneration resorbable barrier per site

CDT codes (informational)CPT

D3431	Biological materials to aid in soft and osseous tissue regeneration in conjunction with periradicular surgery
D4265	Biologic materials to aid in soft and osseous tissue regeneration, per site
D4266	Guided tissue regeneration resorbable barrier per site

Provider Actions and Requirements

Prior Authorization

Prior Authorization / Contract Guidance

Prior authorization depends on the member's group contract. When coverage is governed by a specific group contract, follow the contract requirements and ensure clinical indications are documented as described below.

Follow group contract prior authorization rules where applicable.

Step Therapy

No step therapy requirements are specified in this policy. Coverage is contingent on meeting documentation requirements and any applicable group contract terms.

No step therapy is mandated by this policy; however, plan or group contract terms may impose additional utilization management.
Coverage decisions remain documentation-dependent.

Documentation Required

Required Documentation

Providers must supply diagnostic documentation to support coverage for biologic materials. Required items include pretreatment periapical radiographs dated within 12 months and current, dated 6‑point periodontal charting.

Pretreatment periapical radiographic images of diagnostic quality, properly oriented, identified, and dated within 12 months.
Current dated 6‑point periodontal charting indicating a minimum of 5 mm pocket depths.

Denial Risk

Documentation-Dependent Coverage / Denial Risk

Coverage is documentation‑dependent. Failure to provide required radiographs, current periodontal charting, and a letter of rationale (when requested) may result in non‑coverage or claim denial.

A letter of rationale explaining the necessity of the regeneration procedure and the specific biologic material used may be requested (examples: PRP, Emdogain, recombinant human BMP, GEM 21S9).
Use of biologic materials may not be considered when performed in conjunction with soft tissue grafting, bone grafts, guided tissue regeneration, ridge augmentation, periradicular surgery, placement within extraction sites, or when utilized with other regenerative materials — document clinical justification if applicable.

Background

Biologic materials and tissue engineering (regenerative medicine) are used in dentistry to promote regeneration of damaged soft and osseous tissues rather than relying solely on autografts or allografts. These adjunctive regenerative therapies can be applied to periodontal defects of natural teeth and to peri-implant defects, and may include products such as platelet-rich plasma, enamel matrix derivative, or recombinant bone morphogenetic proteins. Coverage of such therapies is reviewed against generally accepted standards of dental practice and is subject to the member's group contract terms.

Definitions

Tissue engineering / regenerative medicine — definition

DefinitionA process by which damaged tissues are regenerated using biological substitutes that restore, maintain, or improve tissue function rather than using autografts or allografts; in dentistry, these adjunctive regenerative therapies are applied to periodontal defects of natural teeth and dental implants.

PurposeTo regenerate soft and osseous tissues as an alternative to grafting, supporting restoration and maintenance of tissue function.

Clinical applicationUsed as adjunctive regenerative therapy in dentistry for treatment of periodontal disease defects of natural teeth and dental implants.

Generally accepted standards of dental practice — definition

Core sourcesCredible scientific evidence published in peer‑reviewed dental literature generally recognized by the practicing dental community.

Professional guidanceSpecialty society recommendations and criteria relevant to the clinical area.

Expert opinionViews of recognized practicing dentists in the relevant clinical area.

Other factorsAny other relevant factors from credible sources that inform standards of care.